SOURCE: Trend Exploration, Inc.

September 13, 2010 06:30 ET

TRDX and Genesis Biopharma, Inc. Believe the Future Looks Bright Regarding Their Potential Cure for Painful Diabetic Neuropathy (PDN) -- A Billion Dollar Market Opportunity

JERICHO, NY--(Marketwire - September 13, 2010) -  SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today announces that it believes that the future looks very bright for itself and its sublicense partner, Montreal-based Genesis Biopharma, Inc., as they continue making progress regarding their new compound in development for the treatment and potential cure of Painful Diabetic Neuropathy (PDN).

According to the International Diabetes Federation the global health expenditure on diabetes is expected to total at least USD 376 billion in 2010 and USD 490 billion in 2030. (http://www.idf.org/webdata/docs/PIIS0168822710000495.pdf)

Back in 2003 the American Diabetes Association estimated that in the U.S. the total annual cost of treating diabetic peripheral neuropathy and its complications was $10.91 billion. (http://care.diabetesjournals.org/content/26/6/1790.full)

ABOUT PDN:

PDN is one of many complications of diabetes. Forty to fifty percent of diabetic patients may develop PDN over 15 to 20 years. PDN is present in 11.6% of patients with Type I diabetes and 32.1% of patients with Type II diabetes. PDN may present itself as a progressive build-up of unpleasant sensory symptoms including tingling (paraesthesia), burning pain, radiating pain down the legs and toes and lancinating or contact pain. The pain is more severe during the night and often prevents sleep. Some patients may be in a constant state of tiredness because of sleep deprivation while others are unable to maintain employment.

  1. According to the World Health Organization there are approximately 220 million people worldwide who have diabetes

    (http://www.who.int/mediacentre/factsheets/fs312/en/). In the U.S., according to the 2007 National Diabetes Fact Sheet, a total of 23.6 million had diabetes of which 17.9 million were already diagnosed and the rest, 24%, were undiagnosed.

    (http://www.diabetes.org/diabetes-basics/diabetes-statistics/). If you add the undiagnosed cases to the 220 million reported by the World Health Organization the total number could exceed 270 million worldwide.

  2. Diabetic neuropathy can cause nerve damage in the feet that leads to decrease or loss of sensation. As a result, a blister or a cut can go unnoticed. Any infection that might ensue can result in tissue death (gangrene) and in some cases severe damage can lead to amputation of toe, foot or even leg. Each year about 80,000 - 84,000 amputations are performed in the U.S. alone (See Diabetes-Related Amputation Statistics:
    http://www.isletsofhope.com/diabetes/complications/amputation_1.html#diabetes).

    How many of these amputations could have been avoided had a solution been made available?

Mr. Leo Stella, CEO of Genesis, has stated: "Until now, there is absolutely no mechanism based treatment that can reverse neuropathy associated with diabetes. Drugs exist that have a temporary effect on the pain, but these drugs cannot cure the cause. The goal of Genesis Biopharma is to develop a drug that will cure this terrible condition."

Dr. Jan Stahl, CEO of TRDX, commented: "The opportunity is very significant for all the stakeholders in this PDN solution. We will continue our efforts to make this potential cure a reality and deliver quality value for our shareholders."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called "amide bonds").

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

Contact Information